SCHEDULE 13G/A: Biotechnology Value Fund Affiliates Report 1.8% Stake in enGene Holdings via Warrants

Multiple entities affiliated with Biotechnology Value Fund have filed an amended Schedule 13G, disclosing beneficial ownership of 945,402 common shares of enGene Holdings Inc. through warrants, representing approximately 1.8% of the outstanding class.

Summary

• Biotechnology Value Fund, L.P. (BVF) and its affiliated entities, including BVF I GP LLC, Biotechnology Value Fund II, L.P. (BVF2), BVF II GP LLC, Biotechnology Value Trading Fund OS LP, BVF Partners OS Ltd., BVF GP Holdings LLC, BVF Partners L.P., BVF Inc., and Mark N. Lampert, collectively reported beneficial ownership in enGene Holdings Inc.
• As of January 29, 2025, the Reporting Persons and a Partners managed account held exchange-traded warrants exercisable for an aggregate of 945,402 Common Shares of enGene Holdings Inc.
• These warrants have an exercise price of $11.50 per share and became exercisable 30 days after the October 31, 2023, combination between enGene Holdings Inc. and Forbion European Acquisition Corp.
• The warrants are set to expire on October 31, 2028.
• The aggregate beneficial ownership of 945,402 shares represents approximately 1.8% of enGene Holdings Inc.'s outstanding Common Shares, based on a total of 51,922,078 shares outstanding as of December 16, 2024, plus the shares underlying these warrants.
• Specifically, BVF beneficially owned 505,835 shares (less than 1%), BVF2 beneficially owned 383,352 shares (less than 1%), and Trading Fund OS beneficially owned 43,786 shares (less than 1%).
• BVF GPH may be deemed to beneficially own approximately 1.7% of the outstanding shares, while Partners, BVF Inc., and Mr. Lampert may be deemed to beneficially own approximately 1.8%.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the company's performance. The continued holding of a stake by a specialized fund is neutral to slightly positive for investor confidence.

Positives

• The continued holding of a stake by a specialized biotechnology investment fund (Biotechnology Value Fund) may signal confidence in enGene Holdings Inc.'s long-term prospects, particularly given their focus on the biotechnology sector.

Negatives

• NA

Risks

• The beneficial ownership is primarily through warrants, which means the value is subject to the underlying share price exceeding the $11.50 exercise price. If the share price remains below this threshold, the warrants may not be exercised or may lose value.
• The warrants have an expiration date of October 31, 2028, after which they will become worthless if not exercised.

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from enGene Holdings Inc. regarding its future performance or operations.

Industry Context

The filing highlights the continued interest of specialized biotechnology investment funds, such as Biotechnology Value Fund, in companies within the biotech sector. Such investments can reflect a strategic long-term view on the potential of specific therapeutic areas or technological platforms, aligning with broader trends of targeted investments in innovative life sciences companies.

Stakeholder Impact

• Shareholders: The filing provides transparency regarding a significant institutional investor's stake, which can influence market perception and potentially provide a signal of investor confidence or interest in the company.

Key Dates

Keywords

enGene Holdings Inc., Biotechnology Value Fund, SEC filing, Schedule 13G, beneficial ownership, warrants, common shares, institutional investor, biotechnology, investment fund